SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

ImmunityBio is trending following Anktiva's EU approval and a major distribution partnership, alongside a US FDA submission and strategic Saudi Arabia collaborations, fueling community excitement about its cancer-fighting potential and a brewing short squeeze among high short interest.

GRAIL, Inc. operates as a commercial-stage healthcare company, which engages in the development of a technology for early detection of cancer. It utilizes machine learning, software, and automation to detect and identify multiple deadly cancer types in earlier stages. The company was founded by Jeffrey T. Huber, William H. Rastetter, Mostafa Ronaghi, and Richard D. Klausner on September 11, 2015 and is headquartered in Menlo Park, CA.

GRAIL Inc.

GRAIL is trending after its cancer screening trial missed a primary endpoint for statistically significant reduction in late-stage diagnoses, sparking a sharp sell-off and intense debate. While bears foresee further collapse, many bulls argue the market overreacted, pointing to the test's clinical benefits, strong cash reserves, and recent institutional investments as indicators of its long-term potential in multi-cancer early detection.

Klarna Group Plc is a global digital bank and flexible payments provider. It operates through an AI-powered payments and commerce network that empowers people to pay smarter, with a mission to be available everywhere, for everything. The company was founded by Gustav Erik Niklas Adalberth, Karl Anders Victor Jacobsson, and Sebastian Marcin Siemiatkowski in 2005 and is headquartered in London, the United Kingdom.

Klarna Group plc

KLAR is trending due to a steep stock decline following its Q4 earnings report, which showed a net loss driven by significantly increased credit loss provisions despite strong revenue growth. The community is divided, with many bears questioning the long-term viability and profitability of the "Buy Now, Pay Later" model, while some bulls contend the market is overreacting to accounting technicalities and see potential in the company's expanding user base and strategic partnerships.

Celsius Holdings, Inc. engages in the development, marketing, sale, and distribution of functional drinks and liquid supplements. It also offers post-workout functional energy drinks and protein bars. The company was founded in April 2004 and is headquartered in Boca Raton, FL.

Celsius Holdings Inc

Celsius Holdings is trending following management's CAGNY conference updates on significant distribution and shelf space gains, as community discussion remains sharply divided between strong growth projections and persistent concerns about CEO communication and a potential low-ball PepsiCo acquisition.

$SWEAT is the beating heart of the Movement Economy—a groundbreaking token that transforms physical activity into real-world value. Minted through movement, $SWEAT rewards your steps with a crypto asset that you can earn, trade, or grow. The team states that their app has increased their users’ physical activity by an average of 20%, creating a healthier society and reducing burdens on global healthcare systems. With over 20 million holders, SWEAT is eliminating barriers and making Web3 accessible to everyone, one step at a time.

Sweat Economy

Sweat Economy (SWEAT) is trending as a comprehensive token analysis highlights recent scarcity boosts from token burns, its expanding utility as a multi-chain "universal gas token," and growing Web3 gaming features. The community actively discusses its unique "move-to-earn" model, expressing long-term optimism for its potential as a reward for physical activity.

Tandem Diabetes Care, Inc. engages in the design, development, and commercialization of products for people with insulin-dependent diabetes. Its products include Tandem Mobi System and t:slim X2 Insulin Pump. The company was founded by Paul M. DiPerna on January 27, 2006 and is headquartered in San Diego, CA.

Tandem Diabetes Care Inc

Tandem Diabetes Care is a focus of discussion following its recent earnings, which generated mixed reactions among the community despite reported beats on some metrics, and is further driven by anticipation for its Control-IQ+ technology and strategic partnerships with Abbott. Many investors see the stock as undervalued given these developments and its efforts to enhance competitiveness in the evolving diabetes management sector.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

Applovin is trending amid intense speculation around a potential partnership with OpenAI to monetize ChatGPT, and rumors of the company developing its own social media platform. The community is sharply divided, with bulls highlighting the stock's strong fundamentals and oversold status after a significant dip, while skeptics question the rumors and cite broader AI disruption fears.

Transocean Ltd. engages in the provision of offshore contract drilling services for oil and gas wells. It also owns and operates offshore drilling fleets such as ultra-deepwater, harsh environment, deepwater, and midwater rigs. The company was founded in 1953 and is headquartered in Steinhausen, Switzerland.

Transocean Ltd

Transocean is trending due to its announced all-stock acquisition of Valaris, which creates a dominant offshore drilling entity with an expanded backlog and enhanced pricing power. The market is also reacting to positive adjusted earnings and significant debt reduction, fueling bullish sentiment for a potential short squeeze amidst an offshore sector upcycle.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

Capricor Therapeutics is trending as the community eagerly anticipates the BLA resubmission for its Duchenne Muscular Dystrophy therapy, Deramiocel, expected by month-end after strong Phase 3 data. Investors are noting increasing institutional interest and potential regulatory shifts, positioning the stock as a compelling, undervalued biotech play amidst broader market rotations.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Chatham, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is trending as its preliminary financial results highlight strong initial sales for Tonmya, prompting community discussion about the new fibromyalgia treatment's promising launch trajectory compared to other CNS drugs. Despite historical concerns regarding dilution, increasing institutional ownership and the company's significant cash reserves are driving a narrative that the stock is currently undervalued given Tonmya's commercial traction and pipeline potential.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

$KGC 

$VGZ $GOLD $RGLD $DRD 
Wall Street Bullish on Kinross Gold Corporation (KGC) Ahead of its Fiscal Q4 2025 Earnings

Kinross Gold Corporation (NYSE:KGC) is one of the High Growth International Stocks to Buy Now. The company is set to release its fiscal Q4 2025 earnings on February 18, 2026. The Street remains bullish on the stock mainly due to surging gold prices and increased geopolitical uncertainties.

Recently, on February 4, Anita Soni from CIBC raised the price target on Kinross Gold Corporation (NYSE:KGC) from $38.5 to $54 and maintained a Buy rating

https://finance.yahoo.com/news/wall-street-bullish-kinross-gold-101950841.html

​Kinross Gold Corporation (NYSE:KGC) is one of the High Growth International Stocks to Buy Now. The company is set to release its fiscal Q4 2025 earnings on February 18, 2026. The Street remains bullish on the stock mainly due to surging gold prices and increased geopolitical uncertainties.

Yahoo Finance

Wall Street Bullish on ​Kinross Gold Corporation (KGC) Ahead of its Fiscal Q4 2025 Earnings

StockTwits For Android 

Kinross Gold Corp.

Vista Gold Corp.

Gold.com Inc.

Royal Gold, Inc.

DRDGOLD Ltd.

 
Wall Street Bullish on Kinross Gold Corporation (KGC) Ahead of its Fiscal Q4 2025 Earnings

Kinross Gold Corporation (NYSE:KGC) is one of the High Growth International Stocks to Buy Now. The company is set to release its fiscal Q4 2025 earnings on February 18, 2026. The Street remains bullish on the stock mainly due to surging gold prices and increased geopolitical uncertainties.

Recently, on February 4, Anita Soni from CIBC raised the price target on Kinross Gold Corporation (NYSE:KGC) from $38.5 to $54 and maintained a Buy rating

